Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 833 matching trials from the live ClinicalTrials.gov search.
Filters: "triple-negative" Condition: Breast Cancer Clear all
Completed Phase 1 Interventional

cMet CAR RNA T Cells Targeting Breast Cancer

NCT01837602
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions
cMet RNA CAR T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 13, 2026, 9:22 PM EDT
Not listed Phase 2 Interventional

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

NCT00777673
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 13, 2026, 9:22 PM EDT
Not listed Phase 1 Interventional

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531
View directory record Official record
Conditions
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions
IPI-549 (eganelisib), Nivolumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Withdrawn Not applicable Interventional

Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning

NCT03340402
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, AlignRT
Radiation · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational

Triple Negative Breast Cancer Biomarker Study

NCT01111175
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
Denver, Colorado • Elizabeth City, North Carolina • Portland, Oregon + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03853707
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

NCT04916002
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
Interventions
vidutolimod, cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

NCT02996825
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacological Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Duarte, California • Upland, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Daratumumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

NCT02048059
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Phase 1 Interventional

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

NCT03596073
View directory record Official record
Conditions
Breast Cancer
Interventions
Topical Calcipotriene Ointment, Topical Vaseline
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Not yet recruiting Phase 2 Interventional

US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy

NCT07862751
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging, Ultrasound Imaging, Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

NCT00894504
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Panitumumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
17
States / cities
Thousand Oaks, California • Aventura, Florida • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

AZD8186 First Time In Patient Ascending Dose Study

NCT01884285
View directory record Official record
Conditions
Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
Interventions
Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

NCT05852691
View directory record Official record
Conditions
Breast Cancer
Interventions
Tobemstomig, Pembrolizumab, Nab-Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Alamitos, California • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Withdrawn Phase 2 Interventional

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

NCT03644589
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Interventions
Pembrolizumab, Cisplatin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178
View directory record Official record
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions
There are no interventions in this observational study.
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

NCT03775850
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
Interventions
EDP1503, Pembrolizumab
Biological
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Interventions
Carboplatin, Paclitaxcel, Pembrolizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Syracuse, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

NCT07652242
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose)
Biological · Drug
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Grand Rapids, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Phase 1 Interventional

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

NCT05111561
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 9:22 PM EDT